After a global consensus process involving more than 14,000 survey responses and input from 56 organizations worldwide, the condition previously known as polycystic ovary syndrome (PCOS) has been renamed. The new name is PMOS1, which stands for polyendocrine metabolic ovarian syndrome. The change reflects a shift in how the medical community understands a condition that affects an estimated 170 million women globally.
The old name was always somewhat misleading. The condition does not actually involve pathological ovarian cysts, despite what the name suggested. What appeared as cysts on some ultrasounds are actually immature follicles, which are a symptom of hormonal dysfunction, not the cause of it. This naming confusion had real consequences. By centering the ovaries, the old terminology obscured the condition’s true nature as a multi-system syndrome involving hormones, metabolism, and ovarian function.
Research confirms the scope of the problem. A 2025 study found that while population-based data shows PCOS prevalence between 4 and 19.6 percent, health system records capture only 0.2 to 5.2 percent. This diagnostic gap is not evenly distributed. Studies show that Black and African American patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.
What the new name encompasses
The new name can be broken down into three components. Polyendocrine means the condition involves multiple hormone systems, including reproductive hormones, androgens like testosterone, insulin, and neuroendocrine hormones that affect everything from mood to metabolism. Metabolic refers to insulin resistance, which is a core feature for many women with this condition and carries significant downstream risks. Ovarian dysfunction remains part of the picture, capturing irregular cycles, anovulation, and fertility challenges, but these are now understood as one piece of a larger puzzle.
The metabolic component deserves particular attention. A 2025 study describes a bidirectional relationship between insulin resistance and symptoms like hyperandrogenism, or excess androgens, and ovulatory dysfunction. The condition itself also increases the risk of type 2 diabetes. This is more evidence of how the condition has reproductive, metabolic, and psychological impacts across a person’s lifespan.
How clearer terminology could improve diagnosis
When clinicians heard the old name, they often looked for ovarian cysts and menstrual irregularities when diagnosing patients. With the new name, the diagnostic lens widens considerably. This matters because many women with this condition do not fit the narrow classic presentation. Some have regular periods. Others present with irregular menstrual cycles but do not have visible follicles on an ultrasound. However, symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers point to the same underlying dysfunction.
The hope is that reframing the condition as metabolic and endocrine, instead of simply gynecological, will prompt earlier and more comprehensive screening. A woman presenting with unexplained weight gain, fatigue, and skin changes might now be evaluated for this condition rather than having her symptoms dismissed or siloed into separate specialty visits.
For those who have been diagnosed with the condition, this name change validates what many have long known. The condition is not just about the ovaries. It is a whole-body condition that deserves whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health. For those who have suspected something was off but have not gotten answers, the evolving understanding of the condition may work in their favor. Experts suggest asking healthcare providers about comprehensive hormone and metabolic testing, not just an ultrasound.
